Ablynx is a Belgian biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. The Company has proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease.
Type
Public
HQ
Gent, BE
Founded
2001
Size (employees)
344 (est)
Website
ablynx.com
Ablynx was founded in 2001 and is headquartered in Gent, BE

Key People/Management at Ablynx

Frank Landolt

Frank Landolt

IP and legal counsel
Guido Gielen

Guido Gielen

VP Human Resources

Ablynx Office Locations

Ablynx has an office in Gent
Gent, BE (HQ)
21 Technologiepark-Zwijnaarde
Show all (1)

Ablynx Financials and Metrics

Ablynx Financials

Ablynx's revenue was reported to be €85.2 m in FY, 2016 which is a 10% increase from the previous period.
EUR

Revenue (FY, 2016)

85.2 m

Revenue growth (FY, 2015 - FY, 2016), %

10%

Net income (FY, 2016)

(1.1 m)

EBIT (FY, 2016)

(28.6 m)

Market capitalization (16-Nov-2016)

584.9 b

Closing share price (16-Nov-2016)

9.6

Cash (31-Dec-2016)

53.4 m
Ablynx's current market capitalization is €584.9 b.
EURFY, 2015FY, 2016

Revenue

77.5 m85.2 m

Revenue growth, %

10%

R&D expense

83.1 m100.3 m

General and administrative expense

11.4 m13.5 m
EURFY, 2015FY, 2016

Cash

3.6 m53.4 m

Accounts Receivable

9.3 m4.8 m

Current Assets

246.1 m242.2 m

PP&E

2.6 m3.7 m
EURQ2, 2015Q2, 2016

Cash

53.4 m26.4 m

Accounts Receivable

4.8 m4.1 m

Current Assets

242.2 m210.5 m

PP&E

3.7 m3.9 m
EURFY, 2015FY, 2016

Net Income

(54.5 m)(1.1 m)

Depreciation and Amortization

1.1 m1.8 m

Accounts Receivable

11.6 m(86 k)

Accounts Payable

(45.2 m)(43.2 m)
EURQ2, 2016Q2, 2017

Net Income

22.8 m(25.3 m)

Depreciation and Amortization

885 k1.5 m

Accounts Receivable

(3.8 m)(568 k)

Accounts Payable

(21.4 m)(7.9 m)
Show all financial metrics

Ablynx Operating Metrics

Ablynx's Clinical Programs was reported to be 45 in Q2, 2017
Q2, 2017

Clinical Programs

45

Patents (US)

50

Patents (foreign)

180

Patents and Patent Applications

400
Show all operating metrics

Ablynx Market Value History

Ablynx's Web-traffic and Trends

Ablynx Online and Social Media Presence

Ablynx News and Updates

VC-backed Albynx debuts U.S. IPO

Ablynx, a Belgian biopharmaceutical company, has raised $200 million for its U.S. IPO after pricing its 11.4 million shares at $17.50 per share. The stock began trading October 25, 2017 on the NASDAQ under the ticker symbol “ABLX.” BofA Merrill Lynch, J.P. Morgan and Jefferies are the lead underwrit…

VC-backed Ablynx files for IPO

Ablynx, a Belgian biopharmaceutical company, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. Ablynx, which currently trades on the Euronext Brussels, is planning on listing its U.S. stock on the NASDAQ under the ticker symbol ABLX…

Ablynx Company Life and Culture

You may also be interested in